Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

INMB US Equity

Inmune Bio, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1711754 · FY ends Dec 31
$2.23
+0.12 (+5.69%)
USD · as of 2026-08-19 · marketstack

INMB · 10-K · period ended 2024-12-31

← all INMB documents
filed 2025-03-27 · EDGAR original ↗

Our rendering of the filing — original pagination and typography are not reproduced, and tables are reduced to their short label cells (the figures live on FA). Nothing is summarized: every line below is the filing's own text.

blocks 1,2431,842 of 3,656346k characters rendered

Item 1a. Risk Factors

Summary of Risk Factors

Below is a summary of the

principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that

we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under

the heading “Risk Factors” and should be carefully considered, together with other information in this Form 10-K and our other

filings with the SEC, before making an investment decision regarding our common stock.

● We must comply with significant government regulations.

29

● The price of our common stock may be volatile.

You should carefully consider

the risks described below as well as other information provided to you in this document, including information in the section of this

document entitled “Information Regarding Forward Looking Statements.” If any of the following risks actually occur, the Company’s

business, financial condition or results of operations could be materially adversely affected, the value of the Company’s Common

Stock could decline, and you may lose all or part of your investment.

RISKS RELATED TO OUR BUSINESS

There is doubt about our ability to continue

as a going concern.

As of December 31, 2024, the

Company had an accumulated deficit of $163,104,000. Losses have principally occurred as a result of the substantial resources required

for research and development of the Company’s product candidates which included the general and administrative expenses associated

with its organization and product development as well as the lack of sources of revenues until such time as the Company’s products

are commercialized. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the 12

months from the issuance date of these financial statements. These financial statements do not include any adjustments to reflect the

possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result

from the outcome of these uncertainties. Management intends to pursue additional funding and implement its strategic plan to allow the

opportunity for the Company to continue as a going concern, however, there cannot be any assurance that we will be successful in doing

so. The opinion of our independent registered public accounts on our audited financial statements for the year ended December 31, 2024,

contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.

There is no assurance that

we will be successful in raising the additional funds needed to fund our business plan. If we are not able to raise sufficient capital

in the near future, our continued operations will be in jeopardy and we may be forced to cease operations and sell or otherwise transfer

all or substantially all of our remaining assets.

We face intense competition in the markets

targeted by our lead product candidates. Many of our competitors have substantially greater resources than we do, and we expect that all

of our product candidates under development will face intense competition from existing or future drugs.

We expect that our product

candidates under development, if approved, will face intense competition from existing and future drugs marketed by large companies. These

competitors may successfully market products that compete with our products, successfully identify drug candidates or develop products

earlier than we do, or develop products that are more effective, have fewer side effects or cost less than our products, if any.

Additionally, if a competitor

receives FDA approval before we do for a drug that is similar to one of our product candidates, FDA approval for our product candidate

may be precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA by the competitor of patents covering

its newly-approved drug product. Periods of non-patent exclusivity for new versions of existing drugs such as our current product candidates

can extend up to three and one-half years. See the section entitled “Government Regulation.”

These competitive factors

could require us to conduct substantial new research and development activities to establish new product targets, which would be costly

and time-consuming. These activities would adversely affect our ability to commercialize products and achieve revenue and profits.

30

Competition and technological change may

make our product candidates and technologies less attractive or obsolete.

We compete with established

pharmaceutical and biotechnology companies that are pursuing other forms of treatment for the same indications we are pursuing and that

have greater financial and other resources. Other companies may succeed in developing products earlier than us, obtaining FDA approval

for products more rapidly, or developing products that are more effective than our product candidates. Research and development by others

may render our technology or product candidates obsolete or noncompetitive or result in treatments or cures superior to any therapy we

develop. We face competition from companies that internally develop competing technology or acquire competing technology from universities

and other research institutions. As these companies develop their technologies, they may develop competitive positions that may prevent,

make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue we would be able to derive

from the sale of any products.

There can be no assurance

that any of our product candidates will be accepted by the marketplace as readily as these or other competing treatments. Furthermore,

if our competitors’ products are approved before ours, it could be more difficult for us to obtain approval from the FDA. Even if

our products are successfully developed and approved for use by all governing regulatory bodies, there can be no assurance that physicians

and patients will accept our product(s) as a treatment of choice.

Furthermore, the pharmaceutical

research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith are numerous and significant.

The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude us from forecasting revenues

or income with certainty or even confidence.

We

have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently

profitable, and we may never achieve or sustain profitability.

We were formed in September

2015 and have only a limited operating history and have incurred losses since our formation. We continue to incur significant development

and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses

in each period since our inception, resulting in substantial doubt in our ability to continue as a going concern. We reported a net loss

of $42.1 million and $30.0 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, we

had cash and cash equivalents of $20.9 million and $35.8 million, respectively.

We expect to continue to incur significant losses for the foreseeable

future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our

product candidates and now that we are no longer an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933,

as amended. As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank

Act, as well as rules adopted, and to be adopted, by the SEC and The Nasdaq Stock Market LLC. We also expect that compliance with the

auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and increased disclosure requirements will increase our legal

and financial compliance costs. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and

our ability to generate revenues, if any. The costs of advancing product candidates into each clinical phase tend to increase substantially

over the duration of the clinical development process. Therefore, the total costs to advance any of our product candidates to marketing

approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical

product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to

begin generating revenue from the commercialization of any products or achieve or maintain profitability.

The costs of advancing product

candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the

total costs to advance any of our product candidates to marketing approval in even a single jurisdiction will be substantial. Because

of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing

or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products

or achieve or maintain profitability.

Furthermore,

our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial

additional risks and uncertainties. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable

future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity

and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability

to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations,

or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve

profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve

or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially and adversely

affected.

Even if we are able to commercialize any

product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement

practices or healthcare reform initiatives that could harm our business.

The commercial success of

our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates

will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government

health administration authorities (such as Medicare and Medicaid), private health coverage insurers and other third-party payors. If reimbursement

is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even

if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish and maintain pricing sufficient

to realize a meaningful return on our investment.

31

There is significant uncertainty

related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new

drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed.

In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some non-U.S. markets,

prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result,

we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial

launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale

of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates,

even if our product candidates obtain marketing approval.

We are subject to various government regulations.

The manufacture and sale of

human therapeutic products in the U.S. and foreign jurisdictions are governed by a variety of statutes and regulations. These laws require

approval of manufacturing facilities, controlled research and testing of products and government review and approval of a submission containing

manufacturing, preclinical and clinical data in order to obtain marketing approval based on establishing the safety and efficacy of the

product for each use sought, including adherence to current cGMP during production and storage, and control of marketing activities, including

advertising and labeling.

The products we are currently

developing will require significant development, preclinical and clinical testing and investment of substantial funds prior to its commercialization.

The process of obtaining required approvals can be costly and time-consuming, and there can be no assurance that we develop successfully

this product or any future products, or that this product or any future products we develop will prove to be safe and effective in clinical

trials or receive applicable regulatory approvals. Potential investors and shareholders should be aware of the risks, problems, delays,

expenses and difficulties which we may encounter in view of the extensive regulatory environment which controls our business.

If we are unable to keep up with rapid technological

changes in our field or compete effectively, we will be unable to operate profitably.

We are engaged in a rapidly

changing field. Other products and therapies that will compete directly with the products that we are seeking to develop and market currently

exist or are being developed. Competition from fully integrated pharmaceutical companies and more established biotechnology companies

is intense and is expected to increase. Most of these companies have significantly greater financial resources and expertise in discovery

and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing than us. Smaller companies

may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established

biopharmaceutical or biotechnology companies. Many of these competitors have significant products that have been approved or are in development

and operate large, well-funded discovery and development programs. Academic institutions, governmental agencies and other public and private

research organizations also conduct research, seek patent protection and establish collaborative arrangements for therapeutic products

and clinical development and marketing. These companies and institutions compete with us in recruiting and retaining highly qualified

scientific and management personnel. In addition to the above factors, we will face competition based on product efficacy and safety,

the timing and scope of regulatory approvals, availability of supply, marketing and sales capability, reimbursement coverage, price and

patent position. There is no assurance that our competitors will not develop more effective or more affordable products, or achieve earlier

patent protection or product commercialization, than our own.

Other companies may succeed

in developing products earlier than ourselves, obtaining FDA and European Medicines Agency (“EMA”) approvals for such products

more rapidly than we will, or in developing products that are more effective than products we propose to develop. While we will seek to

expand our technological capabilities in order to remain competitive, there can be no assurance that research and development by others

will not render our technology or products obsolete or non-competitive or result in treatments or cures superior to any therapy we develop,

or that any therapy we develop will be preferred to any existing or newly developed technologies.

We may request priority review for our product

candidate in the future. The FDA may not grant priority review for our product candidate. Moreover, even if the FDA designates such product

for priority review, that designation may not lead to a faster regulatory review or approval process and, in any event, would not assure

FDA approval.

We may be eligible for priority

review designation for our product candidate if the FDA determines such product candidate offers major advances in treatment or provides

a treatment where no adequate therapy exists. A priority review designation means that the goal for the FDA is to take action on an application

in six months, rather than the standard review period of ten months. The FDA has broad discretion with respect to whether or not to grant

priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or

status, the FDA may decide not to grant it. Thus, while the FDA has granted priority review to other oncology disease products, our product

candidate, should we determine to seek priority review, may not receive similar designation. Moreover, even if our product candidate is

designated for priority review, such a designation does not necessarily mean a faster regulatory review process or necessarily confer

any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee

approval within an accelerated timeline or thereafter.

32

We believe we may in some instances be able

to secure approval from the FDA or comparable non-U.S. regulatory authorities to use accelerated development pathways. If we are unable

to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate,

which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals.

We anticipate that we may

seek an accelerated approval pathway for our product candidates. Under the accelerated approval provisions in the Federal Food, Drug,

and Cosmetic Act, or FDCA, and the FDA’s implementing regulations, the FDA may grant accelerated approval to a product designed

to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination

that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical

benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given

disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such

as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not

itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect

on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other

clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may

not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted,

accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval

confirmatory studies to verify and describe the drug’s clinical benefit. If such post-approval studies fail to confirm the drug’s

clinical benefit, the FDA may withdraw its approval of the drug.

Prior to seeking such accelerated

approval, we will seek feedback from the FDA and will otherwise evaluate our ability to seek and receive such accelerated approval. There

can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a New Drug Application,

or NDA, for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance

that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development,

review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval

or under another expedited regulatory designation (e.g., breakthrough therapy designation), there can be no assurance that such submission

or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The

FDA or other non-U.S. authorities could also require us to conduct further studies prior to considering our application or granting approval

of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate

would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product

candidate and could harm our competitive position in the marketplace.

Clinical drug development involves a lengthy

and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable

to complete the development and commercialization of our product candidate.

Our product candidates are

in early clinical development. Therefore, the risk of failure of our product candidates is high. It is impossible to predict when or if

our product candidates will prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval

from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive

clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Clinical testing is expensive, difficult to

design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur

at any stage of testing. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage

of drug development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence

of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements

and determination by the FDA or any comparable non-U.S. regulatory authority that a drug product is not safe or effective for its intended

uses. It is possible that even if our product candidate has a beneficial effect, that effect will not be detected during clinical evaluation

as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical

trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate

that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of, or intolerability

caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in

fact the case.

33

Success in early development

does not mean that later development will be successful because, for example, drug candidates in later-stage clinical trials may fail

to demonstrate sufficient safety and efficacy despite having progressed through initial clinical trials.

The design of a clinical trial

can determine whether its results will support approval of a product; however, flaws in the design of a clinical trial may not become

apparent until the clinical trial is well advanced or completed. In addition, preclinical and clinical data are often susceptible to varying

interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and

clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of

clinical trials for our product candidate warrant marketing approval, the FDA or comparable non-U.S. regulatory authorities may disagree

and may not grant marketing approval of our product candidate.

In some instances, there can

be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous

factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes

in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Any clinical trials that we

may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidate.

The results of

preclinical studies and early-stage clinical trials may not be predictive of future results. Initial success in clinical trials may not

be indicative of results obtained when these trials are completed or in later-stage trials.

The results of preclinical

studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not

be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative

of results obtained when such trials are completed. In particular, the small number of patients in our planned early clinical trials may

make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results

of our initial clinical trials for XPro may not be predictive of the results of further clinical trials of this drug candidate or any

of our other drug candidates. Moreover, preclinical and clinical data often are susceptible to varying interpretations and analyses, and

many companies that have believed their drug candidates performed satisfactorily in preclinical studies and clinical trials nonetheless

have failed to obtain marketing approval of their products. Our future clinical trials may not ultimately be successful or support further

clinical development of any of our drug candidates. There is a high failure rate for drug candidates proceeding through clinical trials.

A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even

after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business,

results of operations, financial condition and prospects.

Interim top-line

and preliminary data from our planned clinical trials that we announce or publish from time to time may change as more patient data become

available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may

publish interim top-line or preliminary data from our planned clinical trials. Interim data from clinical trials that we may complete

are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient

data becomes available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final

data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be

viewed with caution until the final data is available. Adverse differences between preliminary or interim data and final data could significantly

harm our reputation and business prospects.

If clinical trials of our product candidates

fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable non-U.S. regulators, we may incur additional costs

or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

We are not permitted to commercialize,

market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable non-U.S.

regulatory authorities, such as the EMA, impose similar restrictions. We may never receive such approvals. We must complete extensive

preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidate in humans before we will be

able to obtain these approvals.

Clinical testing is expensive,

difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We have not previously submitted

an NDA to the FDA or similar drug approval filings to comparable non-U.S. regulatory authorities for any product candidate.

34

Any inability to successfully

complete preclinical and clinical development could result in additional costs to us and impair our ability to generate revenues from

product sales, regulatory and commercialization milestones and royalties. In addition, if (1) we are required to conduct additional clinical

trials or other testing of our product candidate beyond the trials and testing than we contemplate, (2) we are unable to successfully

complete clinical trials of our product candidate or other testing, (3) the results of these trials or tests are unfavorable, uncertain

or are only modestly favorable, or (4) there are unacceptable safety concerns associated with our product candidate, we, in addition to

incurring additional costs, may:

● be delayed in obtaining marketing approval for our product candidate;

● not obtain marketing approval at all;

● be subject to additional post-marketing testing or other requirements; or

If we experience any of a number of possible

unforeseen events in connection with clinical trials of any of our product candidates, potential marketing approval or commercialization

of that product candidate could be delayed or prevented.

We may experience numerous

unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval of any of our product candidates,

including:

● participating patients may be subject to unacceptable health risks;

35

Product development costs

for us will increase if we experience delays in testing or pursuing marketing approvals and we may be required to obtain additional funds

to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical

tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant

preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our

product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize

our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, clinical

trial delays may ultimately lead to the denial of marketing approval of our product candidates.

If we experience delays or difficulties

in the enrollment of patients in clinical trials, we may not achieve our clinical development on our anticipated timeline, or at all,

and our receipt of necessary regulatory approvals could be delayed or prevented.

We may not be able to initiate

or continue clinical trials for CORDStrom, INKmune our DN-TNF product platform or any other product candidate if we are unable to locate

and enroll a sufficient number of eligible patients to participate in clinical trials. Patient enrollment is a significant factor in the

timing of clinical trials, and is affected by many factors, including:

● the size and nature of the patient population;

● the severity of the disease under investigation;

● the proximity of patients to clinical sites;

● the eligibility criteria for the trial;

● the design of the clinical trial;

● efforts to facilitate timely enrollment;

● competing clinical trials; and

36

Our inability to enroll a

sufficient number of patients for our clinical trials could result in significant delays or may require us to abandon one or more clinical

trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, delay

or halt the development of and approval processes for our product candidates and jeopardize our ability to achieve our clinical development

timeline and goals, including the dates by which we will commence, complete and receive results from clinical trials. Enrollment delays

may also delay or jeopardize our ability to commence sales and generate revenues from our product candidates. Any of the foregoing could

cause the value of the Company to decline and limit our ability to obtain additional financing, if needed.

We will need to obtain FDA approval of any

proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.

A pharmaceutical product cannot

be marketed in the U.S. or other countries until we have completed rigorous and extensive regulatory review processes, including approval

of a brand name. Any brand names we intend to use for our product candidates will require approval from the FDA regardless of whether

we have secured a formal trademark registration from the U.S. Patent and Trademark Office, or the USPTO. The FDA typically conducts a

review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also

object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed

product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand

name, we will lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant

additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe

the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark

in a timely manner or at all, which would limit our ability to commercialize our product candidates.

37

We may fail to comply with regulatory requirements.

Our success will be dependent

upon our ability, and our collaborative partners’ abilities, to maintain compliance with regulatory requirements, including cGMP,

and safety reporting obligations. The failure to comply with applicable regulatory requirements can result in, among other things, fines,

injunctions, civil penalties, total or partial suspension of regulatory approvals, refusal to approve pending applications, recalls or

seizures of products, operating and production restrictions and criminal prosecutions.

Even if our product candidates receive marketing

approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical

community necessary for commercial success and the market opportunity for the product candidates may be smaller than we estimate.

We have never commercialized

a product. Even if CORDStrom, INKmune, our DN-TNF product platform (INB03 or XPro), or any other product candidate we develop is approved

by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians,

patients, third-party payors and others in the medical community. For example, physicians are often reluctant to switch their patients

from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often

acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products

or they are required to switch therapies due to lack of reimbursement for existing therapies.

Efforts to educate the medical

community and third-party payors on the benefits of our product candidate may require significant resources and may not be successful.

If our product candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues

and we may not become profitable. The degree of market acceptance of INmune or any other product candidate we develop, if approved for

commercial sale, will depend on a number of factors, including:

● the efficacy and safety of the product;

● the potential advantages of the product compared to alternative treatments;

● the prevalence and severity of any side effects;

● the clinical indications for which the product is approved;

● our ability to offer the product for sale at competitive prices;

38

● the strength of sales, marketing and distribution support;

● the approval of other new products for the same indications;

● changes in the standard of care for the targeted indications for the product;

● potential product liability claims.

The potential market opportunities

for our product candidate are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many

assumptions, including industry knowledge and publications, third-party research reports and other surveys. While we believe that our

internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are

inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions

prove to be inaccurate, the actual markets for our product candidate could be smaller than our estimates of the potential market opportunities.

Even if we obtain regulatory approvals for

CORDStrom, INKmune and/or any product from our DN-TNF platform those approvals and ongoing regulation of our products may limit how we

manufacture and market our products, which could prevent us from realizing the full benefit of our efforts.

If we obtain regulatory approvals,

CORDStrom, INKmune and/or the DN-TNF product platform, and the manufacturing facilities used for its production will be subject to continual

review, including periodic inspections, by the FDA and other United States and foreign regulatory authorities. In addition, regulatory

authorities may impose significant restrictions on the indicated uses or marketing of INKmune or other products that we may develop. These

and other factors may significantly restrict our ability to successfully commercialize INKmune.

We and many of our vendors

and suppliers will be required to comply with current Good Manufacturing Practices, or GMP, which include requirements relating to quality

control and quality assurance as well as to the corresponding maintenance of records and documentation. Furthermore, any manufacturing

facilities will need to be approved by regulatory agencies before these facilities can be used to manufacture, and they will also be subject

to additional regulatory inspections. Any material changes we may make to our manufacturing process may require approval by the FDA and

state or foreign regulatory authorities. Failure to comply with FDA or other applicable regulatory requirements may result in criminal

prosecution, civil penalties, recall or seizure of products, partial or total suspension of production or withdrawal of a product from

the market.

We must also report adverse

events that occur when our products are used. The discovery of previously unknown problems with CORDStrom, INKmune, the DN-TNF product

platform or manufacturing facilities used to manufacture CORDStrom, INKmune, or the DN-TNF product platform may result in restrictions

or sanctions on our products or manufacturing facilities, including withdrawal of our products from the market. Regulatory agencies may

also require us to reformulate our products, conduct additional clinical trials, make changes in the labeling of our product or obtain

re-approvals. This may cause our reputation in the marketplace to suffer or subject us to lawsuits, including class action suits.

39

If our product candidates receive marketing

approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects

that were not previously identified, our ability to market the drugs could be compromised.

Clinical trials of our product

candidates will be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it

is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive

effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of our product candidate, we, or others,

discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified,

any of the following adverse events could occur:

● we could be sued and held liable for harm caused to patients;

● the drug may become less competitive; and

● our reputation may suffer.

Any of these events could

have a material and adverse effect on our operations and business.

Any product candidate for which we obtain

marketing approval, along with the manufacturing processes, qualification testing, post-approval clinical data, labeling and promotional

activities for such product, will be subject to continual and additional requirements of the FDA and other regulatory authorities.

These requirements include

submissions of safety and other post-marketing information, reports, registration and listing requirements, good manufacturing practices,

or GMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and recordkeeping.

Even if marketing approval of our product candidate is granted, the approval may be subject to limitations on the indicated uses for which

the product may be marketed or to conditions of approval or contain requirements for costly post-marketing testing and surveillance to

monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of pharmaceutical products

to ensure such products are marketed only for the approved indications and in accordance with the provisions of the approved labeling.

In addition, later discovery

of previously unknown problems with our products, manufacturing processes, or failure to comply with regulatory requirements, may lead

to various adverse results, including:

● restrictions on such products, manufacturers or manufacturing processes;

● restrictions on the labeling or marketing of a product;

● restrictions on product distribution or use;

40

● requirements to conduct post-marketing clinical trials;

● warning letters issued by the FDA or other regulatory authorities;

● withdrawal of the products from the market;

● recall of products, fines, restitution or disgorgement of profits or revenue;

● suspension, revocation or withdrawal of marketing approvals;

● refusal to permit the import or export of our products; and

● injunctions or the imposition of civil or criminal penalties.

We currently have no marketing and sales

organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into

agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.

We currently have no sales,

marketing or distribution capabilities and have no experience as a company in marketing products. If we develop internal sales, marketing

and distribution organization, this will require significant capital expenditures, management resources and time, and we would have to

compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.

If we are unable or decide

not to establish internal sales, marketing and distribution capabilities, we expect to pursue collaborative arrangements regarding the

sales, marketing and distribution of our products. However, we may not be able to establish or maintain such collaborative arrangements,

or if we are able to do so, their sales forces may not be successful in marketing our products. Any revenue we receive would depend upon

the efforts of such third parties, which may not be successful. We may have little or no control over the sales, marketing and distribution

efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves.

We also face competition in our search for third parties to assist us with the sales, marketing and distribution efforts of our product

candidates. There can be no assurance that we will be able to develop internal sales, marketing distribution capabilities or establish

or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.

We face substantial competition from other

pharmaceutical and biotechnology companies and our operating results may suffer if we fail to compete effectively.

The development and commercialization

of new drug products is highly competitive. We expect that we will face significant competition from major pharmaceutical companies, specialty

pharmaceutical companies and biotechnology companies worldwide with respect to our DN-TNF product platform, INKmune and any other of our

product candidates that we may seek to develop or commercialize in the future. Specifically, due to the large unmet medical need, global

demographics and relatively attractive reimbursement dynamics, the oncology market is fiercely competitive and there are a number of large

pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates

for the treatment of cancer. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are

more effective, have fewer or more tolerable side effects or are less costly than any product candidates that we are currently developing

or that we may develop, which could render our product candidates obsolete and noncompetitive.

41

We rely on key personnel and, if we are

unable to retain or motivate key personnel or hire qualified personnel, we may not be able to grow effectively.

We are dependent on certain

members of our management, the loss of services of one or more of whom could materially adversely affect us. In particular, our success

depends to a significant extent upon the continued services of Dr. Raymond J. Tesi, our President and CEO. Dr. Tesi has overseen INmune

Bio since inception and provides leadership for our growth and operations strategy as well as being an inventor of our patents. Although

we have entered into an employment agreement with Dr. Tesi, if he were to nevertheless terminate his employment with us, the loss of the

services of Dr. Tesi, would have a material adverse effect on our growth, revenues, and prospective business. We are also highly dependent

on the other principal members of our management and scientific team. We are not aware of any present intention of any of our key personnel

to leave our company or to retire. The loss of any of our key personnel, or the inability to attract and retain qualified personnel, may

significantly delay or prevent the achievement of our research, development or business objectives and could materially adversely affect

our business, financial condition and results of operations.

Our ability to manage growth

effectively will require us to continue to implement and improve our management systems and to recruit and train new employees. There

can be no assurance that we will be able to successfully attract and retain skilled and experienced personnel.

Product liability lawsuits against us could

divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.

We face an inherent risk of

product liability claims as a result of the clinical testing of our product candidate despite obtaining appropriate informed consent from

our clinical trial participants. We will face an even greater risk if we commercially sell any product that we may develop. For example,

we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing,

marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure

to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under

state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial

liabilities or be required to limit commercialization of our product candidate. Regardless of the merits or eventual outcome, liability

claims may result in:

● decreased demand for our product candidate or products that we may develop;

● injury to our reputation and significant negative media attention;

● withdrawal of clinical trial participants;

● significant costs to defend resulting litigation;

● substantial monetary awards to trial participants or patients;

● loss of revenue;

● reduced resources of our management to pursue our business strategy; and

● the inability to commercialize any products that we may develop.

Although we plan to maintain

general liability insurance, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability

litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, insurance coverage is becoming increasingly

expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against

potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidate,

which could adversely affect our business, financial condition, results of operations and prospects.

42

We will need to increase the size and capabilities

of our organization, and we may experience difficulties in managing this growth.

To execute our business plan,

we will need to rapidly add other management, accounting, regulatory, manufacturing and scientific staff. We currently have 13 full-time

employees in the United States, 9 full-time employees in the United Kingdom and retain the services of additional personnel on an independent

contractor basis. We will need to attract, retain and motivate a significant number of new additional managerial, operational, sales,

marketing, financial, and other personnel, as well as highly skilled scientific and medical personnel, and to expand our capabilities

to successfully pursue our research, development, manufacturing and commercialization efforts and secure collaborations to market and

distribute our products. This growth may strain our existing managerial, operational, financial and other resources. We also intend to

add personnel in our research and development and manufacturing departments as we expand our clinical trial and research capabilities.

Any inability to attract and retain qualified employees to enable our planned growth and establish additional capabilities or our failure

to manage our growth effectively could delay or curtail our product development and commercialization efforts and harm our business.

We are subject to a multitude of manufacturing risks, any of which

could substantially increase our costs and limit supply of our drug candidates.

The process of manufacturing

our drug candidates is complex, highly regulated and subject to several risks. For example, the process of manufacturing our drug candidates

is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or

vendor or operator error. Even minor deviations from normal manufacturing processes for any of our drug candidates could result in reduced

production yields, product defects and other supply disruptions. If microbial, viral, or other contaminations are discovered in our drug

candidates or in the manufacturing facilities in which our drug candidates are made, such manufacturing facilities may need to be closed

for an extended period of time to investigate and remedy the contamination. In addition, the manufacturing facilities in which our drug

candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, epidemics, pandemics, power

failures and numerous other factors.

In addition, any adverse developments

affecting manufacturing operations of our drug candidates may result in shipment delays, inventory shortages, lot failures, withdrawals

or recalls, or other interruptions in the supply of our drug candidates. We also may need to take inventory write-offs and incur other

charges and expenses for drug candidates that fail to meet specifications, undertake costly remediation efforts, or seek costlier manufacturing

alternatives.

We and our contract manufacturers are subject to significant regulation

with respect to manufacturing our drug candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements.

All entities involved in the

preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our drug candidates,

are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical

trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures and the implementation

and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control

of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our drug

candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation

in support of an NDA or marketing authorization application, or MAA, on a timely basis and must adhere to GLP and cGMP regulations enforced

by the FDA, EMA or comparable foreign authorities through their facilities inspection program. Some of our contract manufacturers may

not have produced a commercially approved pharmaceutical product and therefore may not have obtained the requisite regulatory authority

approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection

for compliance with the applicable regulations as a condition of regulatory approval of our drug candidates or any of our other potential

products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation

of our drug candidates or any of our other potential products or the associated quality systems for compliance with the regulations applicable

to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and

are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities

do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until

any violations are corrected to the satisfaction of the regulatory authority, if ever.

43

The regulatory authorities

also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If

any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications

or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial

measures that may be costly or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension

of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us

or third parties with whom we contract could materially harm our business, financial condition and results of operations.

If we or any of our third-party manufacturers fail

to maintain regulatory compliance, the FDA, EMA or comparable foreign authorities can impose regulatory sanctions including, among other

things, refusal to approve a pending application for a drug candidate, withdrawal of an approval, or suspension of production. As a result,

our business, financial condition and results of operations may be materially and adversely affected.

Additionally, if supply from one manufacturer is

interrupted, an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent foreign

regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies or trials if a new

manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in

a delay in our desired clinical and commercial timelines.

These factors could cause us to incur higher costs

and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our drug

candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers

capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.

If we or our third-party manufacturers use

hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.

Our research and development

activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by us and any

third-party manufacturers. We and such manufacturers will be subject to federal, state and local laws and regulations in the United States

governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we will seek to ensure that

our procedures for using, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate

the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we

may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations.

In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources.

We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws

and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts,

which could harm our business, prospects, financial condition or results of operations.

We plan to rely on third parties to conduct

clinical trials for our product candidates. Any failure by a third party to meet its obligations with respect to the clinical development

of our product candidate may delay or impair our ability to obtain regulatory approval for our product candidates.

We plan to rely on contract

research organizations to conduct clinical trials relating to our product candidates. Our reliance on third parties to conduct clinical

trials could, depending on the actions of such third parties, jeopardize the validity of the clinical data generated and adversely affect

our ability to obtain marketing approval from the FDA or other applicable regulatory authorities.

Such clinical trial arrangements

will provide us with information rights with respect to the clinical data, including access to and the ability to use and reference the

Source: SEC EDGAR (public domain) · 10-K for the period ended 2024-12-31, filed 2025-03-27 · accession 0001013762-25-003354

Filing HTML rendered to line-structured narrative text by the shipped reducer (datafeeds.edgar_fulltext.visible_text, keep_table_headers=True): scripts and inline-XBRL headers are dropped, and table content is reduced to its short label cells — numeric table data is not rendered and is therefore not counted. The same rendering is used for every year, so a year-over-year comparison is like for like.

The text is our rendering of the filing, not a facsimile: original pagination, typography and tables are not reproduced, and the numbers live in the financial statements (FA).

The outline locates item HEADINGS in this document. Only Items 1A and 7 have certified boundaries elsewhere in the terminal (the redline and the narrative-overlap number); every span here runs from one heading found to the next heading found.

How the outline was chosen. It is the longest chain of item headings that runs forward through both the document and the standard item order: 22 headings are on that chain and 0 further heading-shaped lines are not — the table-of-contents echo of every item, cross-references and exhibit-list mentions. Each entry's length is measured from its heading to the next heading on the chain.